Adherence Support Approaches in Biomedical HIV Prevention Trials: Experiences, Insights and Future Directions from Four Multisite Prevention Trials

Amico, K.; Mansoor, Leila; Corneli, Amy; Torjesen, Kristine; Straten, Ariane
July 2013
AIDS & Behavior;Jul2013, Vol. 17 Issue 6, p2143
Academic Journal
Adherence is a critical component of the success of antiretroviral-based pre-exposure prophylaxis (PrEP) in averting new HIV-infections. Ensuring drug availability at the time of potential HIV exposure relies on self-directed product use. A deeper understanding of how to best support sustained PrEP adherence remains critical to current and future PrEP efforts. This paper provides a succinct synthesis of the adherence support experiences from four pivotal PrEP trials-Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004, FEM-PrEP, Iniciativa Prophylaxis (iPrEx), and Vaginal and Oral Interventions to Control the Epidemic (VOICE). Notwithstanding variability in the design, population/cohort, formulation, drug, dosing strategy, and operationalization of adherence approaches utilized in each trial, the theoretical basis and experiences in implementation and monitoring of the approaches used by these trials provide key lessons for optimizing adherence in future research and programmatic scale-up of PrEP. Recommendations from across these trials include participant-centered approaches, separating measurement of adherence from adherence counseling, incorporating tailored strategies that go beyond education, fostering motivation, and addressing the specific context in which an individual incorporates and negotiates PrEP use.


Related Articles

  • Adherence in the CAPRISA 004 Tenofovir Gel Microbicide Trial. Mansoor, Leila; Abdool Karim, Quarraisha; Yende-Zuma, Nonhlanhla; MacQueen, Kathleen; Baxter, Cheryl; Madlala, Bernadette; Grobler, Anneke; Abdool Karim, Salim // AIDS & Behavior;May2014, Vol. 18 Issue 5, p811 

    High adherence is key to microbicide effectiveness. Here we provide a description of adherence interventions and the adherence rates achieved in the CAPRISA 004 Tenofovir gel trial. Adherence support for the before-and-after dosing strategy (BAT 24) was provided at enrolment and at each monthly...

  • Assessing Adherence in the CAPRISA 004 Tenofovir Gel HIV Prevention Trial: Results of a Nested Case-Control Study. MacQueen, Kathleen; Weaver, Mark; Loggerenberg, Francois; Succop, Stacey; Majola, Nelisle; Taylor, Doug; Karim, Quarraisha; Karim, Salim // AIDS & Behavior;May2014, Vol. 18 Issue 5, p826 

    Adherence undeniably impacts product effectiveness in microbicide trials, but the connection has proven challenging to quantify using routinely collected behavioral data. We explored this relationship using a nested case-control study in the CAPRISA 004 Tenofovir (TFV) gel HIV prevention trial....

  • 'It's Important to Take Your Medication Everyday Okay?' An Evaluation of Counselling by Lay Counsellors for ARV Adherence Support in the Western Cape, South Africa. Dewing, S.; Mathews, C.; Schaay, N.; Cloete, A.; Louw, J.; Simbayi, L. // AIDS & Behavior;Jan2013, Vol. 17 Issue 1, p203 

    There is growing interest in standard care programmes for antiretroviral (ARV) adherence support. In South Africa, individual counselling following ARV initiation is a main strategy for supporting adherence in the public sector. Egan's client-centred 'Skilled Helper' counselling model is the...

  • HIV pre-exposure prophylaxis. F. Morin, Stephen; Yamey, Gavin; W. Rutherford, George // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/25/2012, Vol. 345 Issue 7871, p10 

    The article reports that the FDA has approved a fixed dose combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC; Truvada) as a once daily pill for prevention of Human immunodeficiency virus (HIV) infection in at risk adults. Studies have shown prophylactic treatment to be...

  • VOICE: Low adherence to tenofovlr among young women.  // Infectious Disease News;Apr2013, Vol. 26 Issue 4, p12 

    The article discusses the Vaginal and Oral Interventions to Control the Epidemic (VOICE) clinical trial conducted by researcher Jeanne Marrazzo and her colleagues which found that adherence to tenofovir was low among young women living in sub-Saharan Africa with a high incidence of HIV infection.

  • Impact of an Adherence Intervention on the Effectiveness of Tenofovir Gel in the CAPRISA 004 Trial. Mansoor, Leila; Karim, Quarraisha; Werner, Lise; Madlala, Bernadette; Ngcobo, Nelisiwe; Cornman, Deborah; Amico, K.; Fisher, Jeffrey; Fisher, William; MacQueen, Kathleen; Karim, Salim // AIDS & Behavior;May2014, Vol. 18 Issue 5, p841 

    High adherence is important in microbicide trials, but no adherence interventions to date have demonstrated empiric improvements in microbicide adherence or effectiveness. Approximately midway during the CAPRISA 004 trial, we implemented a novel adherence intervention (Adherence Support...

  • Masivukeni: Development of a Multimedia Based Antiretroviral Therapy Adherence Intervention for Counselors and Patients in South Africa. Remien, Robert; Mellins, Claude; Robbins, Reuben; Kelsey, Ryan; Rowe, Jessica; Warne, Patricia; Chowdhury, Jenifar; Lalkhen, Nuruneesa; Hoppe, Lara; Abrams, Elaine; El-Bassel, Nabila; Witte, Susan; Stein, Dan // AIDS & Behavior;Jul2013, Vol. 17 Issue 6, p1979 

    Effective medical treatment for HIV/AIDS requires patients' optimal adherence to antiretroviral therapy (ART). In resource-constrained settings, lack of adequate standardized counseling for patients on ART remains a significant barrier to adherence. Masivukeni ('Let's Wake Up' in Xhosa) is an...

  • Prepping for the Future. McEnery, Regina; Kresge, Kristen Jill // VAX;Jan2011, Vol. 9 Issue 1, p1 

    The article discusses the result of the Pre-exposure Prophylaxis Initiative (iPrEx) study for HIV prevention in the U.S. The result of the efficacy trial revealed that daily administration of antiretrovirals (ARVs) emtricitabine (FTC) and tenofovir (TDF) was 44 percent effective in the...

  • Antiretroviral Drug Activity in Macaques Infected during Pre-Exposure Prophylaxis Has a Transient Effect on Cell-Associated SHIV DNA Reservoirs. Cong, Mian-er; Pau, Chou-Pong; Heneine, Walid; GarcĂ­a-Lerma, J. Gerardo // PLoS ONE;11/2/2016, Vol. 11 Issue 11, p1 

    Background: Pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) is a novel HIV prevention strategy. Suboptimal PrEP adherence and HIV infection creates an opportunity for continued antiretroviral drug activity during undiagnosed infection. We...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics